

EURONEXT DERIVATIVES NOTICE

Paris Market No. NO230830DE1

Issue Date: 30 August 2023

Effective Date: 31 August 2023

PROMOTION OF SPOTLIGHT OPTIONS NANOBIOTIX AND SOITEX TO STANDARD SEGMENT

Executive Summary

This Notice informs Members that Spotlight options Nanobiotix (code: NB1) and Soitec (code: LF1) will be promoted to the Standard option segment as from 31 August 2023.

1. Introduction

Spotlight options Nanobiotix (code: NB1) and Soitec (code: LF1) will be promoted to the standard option segment. Euronext will add options series with an initial lifetime of 6, 9 and 12 months.

2. Impacted contracts

On Thursday 31 August 2023, the **Dec-2023**, **Mar-2023** and **Jun-2023** expiry months will be available for trading next to the already listed expiry months in contracts NB1 and LF1.

3. Lifecycle

After the introduction of the new option series, the initial lifecycle for contracts **NB1 and LF1** will be as follows:

Cycle	Expiry months	Initial lifetime (months)
Monthly	Every month	1,2,3
Quarterly	Of the March, June, September, December cycle	6,9,12

The Euronext Markets comprise the markets operated by Borsa Italiana, Euronext Amsterdam, Euronext Brussels, Euronext Dublin, Euronext Lisbon, Euronext Paris and Oslo Børs, referred to respectively as the Milan, Amsterdam, Brussels, Dublin, Lisbon, Paris and Oslo markets, as relevant. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

©2023, Euronext N.V. - All rights reserved.

In case of any additional questions, clients are invited to contact the Client Support team.

Further Information:

Operational Client Support Desk

Telephone:

 Belgium
 +32 2620 0585
 Norway
 +31 20 721 9585

 France
 +33 1 8514 8585
 Portugal
 +351 2 1060 8585

 Ireland
 +353 1 6174 289
 UK
 +44 207 660 8585

 Netherlands
 +31 20 721 9585
 Italy
 +39 02 4541 1399

Email: <u>clientsupport@euronext.com</u> **Service hours:** 08:00 – 19:00 CET/CEST